Related Experiment Video
Updated: Jul 3, 2025
07:29
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.5K
Recent progress in chemoradiotherapy for oesophageal squamous cell carcinoma
Kotoe Oshima1, Takahiro Tsushima1, Yoshinori Ito2
1Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Japanese Journal of Clinical Oncology
|February 11, 2024
Summary
Chemoradiotherapy is standard for oesophageal squamous cell carcinoma but has drawbacks. Combining it with immunotherapy shows promise for improved outcomes and manageable side effects in clinical trials.
Area of Science:
- Oncology
- Gastroenterology
Background:
- Oesophageal squamous cell carcinoma (ESCC) is a prevalent global cancer.
- Chemoradiotherapy is the standard treatment for resectable and locally advanced unresectable ESCC.
- Current chemoradiotherapy approaches face challenges including poor survival rates and treatment toxicities.
Approach:
- This review synthesizes existing clinical data on chemoradiotherapy for ESCC.
- It examines the development of combining chemoradiotherapy with immunotherapy.
- The synergistic mechanisms and early clinical trial findings are discussed.
Key Points:
- Chemoradiotherapy offers a standard treatment but is associated with significant toxicities and limited survival.
- Multimodal strategies, including salvage surgery, are vital for advanced ESCC.
- Palliative chemoradiotherapy plays a role in managing dysphagia.
Conclusions:
- Emerging evidence suggests that combining chemoradiotherapy with immunotherapy may enhance clinical outcomes in ESCC.
- Early phase trials indicate manageable side effects with this combined approach.
- Further investigation is warranted to validate the efficacy and safety of chemoradiotherapy plus immunotherapy for ESCC.
Related Concept Videos
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
203
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
203
01:21Barrett Esophagus-II: Clinical Manifestations and Management
154
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
154